Novartis’s anti-inflammatory drug canakinumab has failed to cut deaths in a trial involving critically ill COVID-19 patients with pneumonia and cytokine release syndrome (CRS).
The CAN-COVID study involved 454 patients at multiple centers across the US, Russia and Europe who were hypoxic but not...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
